Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1348-1354

  Wacheck, Volker ^a   Cejka, Daniel ^a   Sieghart, Wolfgang ^a   Losert, Doris ^a   Strommer, Sabine ^a   Crevenna, Richard ^a   Monia, Brett P ^b   Selzer, Edgar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Gastric cancer; Mcl 1; Molecular targeting

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DOCETAXEL; INTERLEUKIN 6; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STOMACH CANCER;

EID: 33751080104     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3224     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Seminars in Oncology 2004; 31:450-64.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
4. Haglund UH, Wallner B. Current management of gastric cancer. J Gastrointest Surg 2004; 8:907-14.
5. Macdonald JS. Chemotherapy in the management of gastric cancer. J Clin Oncol 2003; 21:276s-9s.
6. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005, (CD004064).
7. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005.
8. Workman P. Drug discovery strategies: Technologies to accelerate translation from target to drug. J Chemother 2004; 16:13-15.
9. Reed JC. Apoptosis mechanisms: Implications for cancer drug discovery. Oncology (Williston Park) 2004; 18:11-20.
10. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993; 90:3516-20.
11. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16:444-54.
12. Akgul C, Moulding DA, White MR, Edwards SW. In vivo localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Lett 2000; 478:72-6.
13. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennett F, Reed JC. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002; 100:1795-801.
14. Fujise K, Zhang D, Liu J, Yeh ET. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 2000; 275:39458-65.
15. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426:671-6.
16. Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, Craig RW. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998; 92:3226-39.
17. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89:630-43.
18. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64:3517-24.
19. Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through upregulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001; 22:1947-53.
20. Selzer E, Thallinger C, Hoeller C, Oberkleiner P, Wacheck V, Pehamberger H, Jansen B. Betulinic acid-induced Mcl-1 expression in human melanoma - Mode of action and functional significance. Mol Med 2002; 8:877-84.
21. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, Craig RW. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994; 54:6348-52.
22. Peek Jr RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2:28-37.
23. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between cytokines and Helicobacter pylori in gastric cancer. Helicobacter 2001; 6:116-24.
24. Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E. Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res 1997; 88:953-8.
25. Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996; 149:1449-57.
26. Maeta Y, Tsujitani S, Matsumoto S, Yamaguchi K, Tatebe S, Kondo A, Ikeguchi M, Kaibara N. Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer 2004; 7:78-84.
27. Chang CS, Chen WN, Lin HH, Wu CC, Wang CJ. Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappaB expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected noncardiac gastric adenocarcinoma. World J Gastroenterol 2004; 10:2232-40.
28. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: Basic principles and recent applications. Nat Rev Drug Discov 2002; 1:503-14.
29. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005; 5:468-79.
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
31. Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E. Mcl-1 is a novel therapeutic target for human sarcoma: Synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 2004; 10:4185-91.
32. Greco WR, Unkelbach HD, Poech G, Suehnel J, Kundi M, Boedeker W. Consensus on concepts and terminology for combined-action assessment: The Saariselkä Agreement. 4th ed. 1992; 65-9.
33. Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22:2950-9.
34. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 upregulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005; 128:2054-65.
35. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-9.
36. Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH. The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. J Leukoc Biol 2000; 68:158-66.
37. Kim R, Ohi Y, Inoue H, Toge T. Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells. Int J Oncol 1999; 15:751-6.
38. Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Gunsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K, Jansen B. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID Mouse xenotransplantation model. J Invest Dermatol 2003; 120:1081-6.
39. Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 2001; 79:587-93.
40. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 2005; 25:709-13.
41. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'eng FK, Chi CW. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996; 91:1417-22.
42. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97:1287-96.